智通财经APP讯，长春高新(000661.SZ)发布2025年半年度报告，报告期内，公司实现营业收入66.03亿 元，同比下降0.54%。实现归属于上市公司股东的净利润9.83亿元，同比下降42.85%。实现归属于上市 公司股东的扣除非经常性损益的净利润10.33亿元，同比下降40.55%。基本每股收益2.44元。 ...

Core Viewpoint - The company reported a revenue of 6.603 billion yuan and a net profit of 983 million yuan for the first half of 2025, indicating short-term performance pressure due to increased R&D investment and market competition, but long-term resilience is expected as innovation results materialize [1] Group 1: Innovation and R&D - The company has emphasized an innovation-driven development strategy, with R&D investment increasing by 17.32% year-on-year to 1.335 billion yuan, accounting for 20.21% of revenue [2] - The approval of the new drug Fuxin Qibai monoclonal antibody (trade name: Jinbeixin) for acute gouty arthritis is a significant highlight, addressing a large patient population in China [2] - The drug offers clinical advantages such as long-term control, rapid efficacy, and safety, filling a gap in long-acting anti-inflammatory targeted therapies [2] Group 2: Product Pipeline and Market Expansion - The company is expanding the indications for Fuxin Qibai monoclonal antibody, with ongoing clinical trials for various conditions, which may become a new growth driver [3] - Jin Sai Pharmaceutical is enhancing its product pipeline in multiple disease areas, focusing on high-demand and high-potential therapeutic fields, including oncology and immunology [3] Group 3: AI Integration and Development - The company is leveraging AI to enhance R&D efficiency, achieving significant improvements in molecular design and process optimization [5] - Seven AI platforms have been established to support various business needs, including drug development and marketing [5] Group 4: Strategic Initiatives and Global Expansion - The company plans to issue H-shares and list on the Hong Kong Stock Exchange, which is expected to deepen its global strategy and accelerate internationalization [7][8] - The listing aims to help the company build a globally influential biopharmaceutical group [8]

Core Viewpoint - Changchun High-tech reported a decline in revenue and net profit for the first half of 2025, indicating potential challenges in its business performance [1][2]. Financial Performance - The company's revenue for the first half of 2025 was 6.603 billion yuan, a year-on-year decrease of 0.54% [1]. - The net profit attributable to shareholders was 983 million yuan, down 42.85% year-on-year [1]. - The basic earnings per share were 2.44 yuan [2]. - The gross profit margin for the first half of 2025 was 83.35%, a decrease of 1.27 percentage points year-on-year [2]. - The net profit margin was 14.11%, down 12.93 percentage points compared to the same period last year [2]. Cost and Expenses - Total operating expenses for the first half of 2025 were 4.256 billion yuan, an increase of 943 million yuan year-on-year [2]. - The expense ratio was 64.46%, up 14.55 percentage points from the previous year [2]. - Sales expenses increased by 23.43%, management expenses by 31.26%, R&D expenses by 30.22%, and financial expenses surged by 85.44% [2]. Shareholder Information - As of the end of the first half of 2025, the total number of shareholders was 109,100, a decrease of 16,000 or 12.78% from the previous quarter [2]. - The average market value per shareholder increased from 318,900 yuan to 370,800 yuan, a growth of 16.28% [2]. Company Overview - Changchun High-tech, established on June 10, 1993, and listed on December 18, 1996, is located in Changchun, Jilin Province [3]. - The company primarily engages in the research, production, and sales of biopharmaceuticals and traditional Chinese medicine, with real estate development and property management as supplementary businesses [3]. - The revenue composition includes 88.40% from biopharmaceuticals, 5.66% from traditional Chinese medicine, 5.61% from real estate, and 0.32% from services [3].

Core Insights - Changchun High-tech reported a revenue of 6.603 billion yuan and a net profit attributable to shareholders of 983 million yuan for the first half of 2025 [1] - The company focuses on biopharmaceuticals and traditional Chinese medicine, with a diversified portfolio including gene engineering, biological vaccines, and modern Chinese medicine [1][2] Financial Performance - In H1 2025, the subsidiary Jinsai Pharmaceutical achieved a revenue of 5.469 billion yuan, a year-on-year increase of 6.17%, but its net profit decreased by 37.35% to 1.108 billion yuan [1] - Baike Bio reported a revenue of 285 million yuan, down 53.93%, with a net loss of 74 million yuan [1] - Huakang Pharmaceutical's revenue was 378 million yuan, a decrease of 3.40%, while its net profit increased by 4.12% to 25 million yuan [1] - Gaoxin Real Estate generated a revenue of 460 million yuan, up 0.76%, but its net profit dropped by 70.34% to 10 million yuan [1] R&D Investment - The company invested 1.335 billion yuan in R&D, a 17.32% increase year-on-year, with R&D expenses reaching 1.155 billion yuan, up 30.22% [2] - R&D investment accounted for 20.21% of total revenue, reflecting a strategic focus on innovation and product development [2] - The increase in R&D spending is attributed to accelerated new product development and enhanced talent acquisition efforts [2] Strategic Focus - The company is strengthening its product layout in endocrine metabolism and pediatric fields, targeting high-demand therapeutic areas such as oncology, immunology, and respiratory diseases [3] - This strategic focus aims to support sustainable development and diversification while pursuing internationalization [3]

Group 1 - The company reported a revenue of 6.603 billion yuan for the first half of the year, representing a year-on-year decrease of 0.54% [1] - The net profit attributable to shareholders of the listed company was 983 million yuan, showing a year-on-year decline of 42.85% [1] - The basic earnings per share were 2.44 yuan [1]

证券代码：000661 证券简称：长春高新 公告编号：2025-084 长春高新技术产业（集团）股份有限公司 总经理工作细则 经第十一届董事会第十一次会议审议通过 | | | 第一章 总则 第一条 为进一步完善长春高新技术产业（集团）股份有限公司 （以下简称"公司"）法人治理结构，明确总经理的职责、权限，规 范总经理的职务行为和总经理议事程序，根据《中华人民共和国公司 法》（以下简称"公司法"）、《上市公司治理准则》《深圳证券交易所 上市公司自律监管指引第 1 号——主板上市公司规范运作》等法律法 规、规范性文件和《公司章程》等有关规定，制定本细则。 第二章 总经理的任职资格与任免程序 第二条 总经理任职应当具备下列条件： （一）具有较丰富的经济理论知识、管理知识及实践经验，具有 较强的经营管理能力； 3 （四）担任因违法被吊销营业执照、责令关闭的公司、企业的法 定代表人，并负有个人责任的，自该公司、企业被吊销营业执照、责 令关闭之日起未逾三年； （五）个人所负数额较大的债务到期未清偿被人民法院列为失信 被执行人； （二）具有较强的组织、协调能力； （三）具有五年以上企业管理或经济管理工作经历，掌握国家有 关 ...

关联（连）交易管理制度（草案） （经公司十一届董事会第十一次会议审议通过，H股发行上市后适用） 第一章 总 则 第一条 为规范长春高新技术产业（集团）股份有限公司（以下 简称"公司"）关联（连）交易行为，保障关联（连）交易的公允性 与合理性，保护公司和全体股东的合法权益，根据《中华人民共和国 公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》 （以下简称"《证券法》"）、《深圳证券交易所股票上市规则》（以 下简称"《股票上市规则》"）、《香港联合交易所有限公司证券上 市规则》（以下简称"《香港上市规则》"）等法律法规、规范性文 件和《长春高新技术产业（集团）股份有限公司章程》（以下简称"公 司章程"）的有关规定，结合公司的实际情况，制订本制度。 第二章 关联（连）人及关联（连）交易认定 证券代码：000661 证券简称：长春高新 公告编号：2025-109 长春高新技术产业（集团）股份有限公司 第二条 公司的关联（连）交易，是指公司或公司控股子公司与 公司关联（连）人之间发生的转移资源或义务的事项，根据《股票上 市规则》，关联交易包括： （一）购买或者出售资产； （二）对外投资（含委托理财、对子公司 ...

证券代码：000661 证券简称：长春高新 公告编号：2025-097 长春高新技术产业（集团）股份有限公司 董事、高级管理人员离职管理制度 （经公司第十一届董事会第十一次会议审议通过） 第一章 总则 第一条 为规范长春高新技术产业（集团）股份有限公司（以下简 称"公司"）董事、高级管理人员离职程序，保障公司治理结构的稳 定性和股东合法权益，公司根据《中华人民共和国公司法》（以下简 称"《公司法》"）、《上市公司章程指引》、《深圳证券交易所上市公司 自律监管指引第 1 号——主板上市公司规范运作》等法律、法规、规 范性文件及《长春高新技术产业（集团）股份有限公司章程》（以下 简称"《公司章程》"）的有关规定，制定本制度。 第二条 本制度适用于公司全体董事（包括独立董事）及高级管理 人员的辞任、任期届满、解任等离职情形。 第二章 离职情形与程序 第三条 公司董事及高级管理人员离职包含任期届满未连任、主动 辞职、退休、被解除职务以及其他导致董事、高级管理人员实际离职 等情形。 第四条 董事可以在任期届满以前辞任。董事辞任应向公司提交书 面辞职报告，公司收到辞职报告之日起辞任生效，公司将在两个交易 日内披露有关情况 ...

证券代码：000661 证券简称：长春高新 公告编号：2025-100 长春高新技术产业（集团）股份有限公司 重大信息内部报告制度 （经公司第十一届董事会第十一次会议审议通过） 第一章 总 则 第一条 为规范长春高新技术产业（集团）股份有限公司（以下简称"本公 司"或"公司"）的重大信息内部报告工作，保证公司内部重大信息的快速传递、 归集和有效管理，及时、准确、全面、完整地披露信息，维护投资者的合法权益， 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司信息披露 管理办法》《深圳证券交易所股票上市规则》（以下简称"《股票上市规则》"） 《长春高新技术产业（集团）股份有限公司章程》（以下简称"《公司章程》"） 《公司信息披露事务管理制度》等有关规定，结合本公司实际，制定本制度。 第二条 公司重大信息内部报告制度是指当出现、发生或即将发生可能对公 司股票及其衍生品种交易价格产生较大影响的情形或事件时，按照本制度规定负 有报告义务的单位、部门、人员，应当在第一时间将相关信息向董事长报告，并 知会董事会秘书的制度。 第三条 本制度适用于公司、分公司、子公司及参股公司。本制度所称"报 告义务人"为公司董事 ...

第三条 授权管理的原则是，在保证公司、股东和债权人合法权 益的前提下，提高工作效率，使公司经营管理规范化、科学化、程 序化。 第四条 股东会是公司的权力机构，依法行使法律、法规、规章、 规范性文件、公司股票上市地证券监管机构或证券交易所的监管规 则、《公司章程》、本制度或公司其他管理制度规定的股东会职权。 公司不得通过授权的形式由董事会或者其他机构或个人代为行使 《公司法》规定的股东会的法定职权。 证券代码：000661 证券简称：长春高新 公告编号：2025-101 长春高新技术产业（集团）股份有限公司 授权管理制度 （经公司十一届董事会第十一次会议审议通过） 第一章 总 则 第一条 为完善长春高新技术产业（集团）股份有限公司（以下 简称"公司"）的治理结构，加强内部控制和风险管理，确保公司 规范运作，保护公司、股东和债权人的合法权益，依据《中华人民 共和国公司法》《中华人民共和国证券法》《深圳证券交易所股票 上市规则》等法律、行政法规以及公司章程的规定，结合公司实际 情况，制定本制度。 第二条 本制度所称的授权，是指由公司股东会对董事会的授 权、董事会对总经理的授权以及公司具体经营管理过程中其他必要 的授 ...